Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
Shionogi’s earnings climbed in FY2016 as soaring royalty revenues from its HIV franchise more than offset a decline in Japan sales, which were weighed down by a biennial drug price revision in April and its divestiture of long-listed products (LLPs),…
To read the full story
Related Article
- Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
May 10, 2018
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
- Shionogi Wants to Zero In on Innovative Drugs, Teshirogi says on LLP Transfer
May 11, 2017
- Shionogi Nets 12.2% Sales Rise on HIV Med Royalty Revenues
November 1, 2016
- Shionogi Scores Record Operating Profit as Royalties Spike
May 12, 2016
BUSINESS
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
February 4, 2026
- Fuji, Richter Expand Gynecology Partnership to Accelerate R&D
February 4, 2026
- Senju, Novartis Ink Promotion Tie-Up for Eye Drug Beovu in Japan
February 4, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…